The next generation biopharmaceuticals
Products
Dear costumers
Due to the current Coronavirus outbreak handling and shipping times might be longer than usual.
We may also need to postpone or cancel orders on short notice if the situation demands it.
Thank you for your support and understanding in these uncertain times.
If you have any questions regarding our products you are welcome to contact biotechnology@affibody.com
Team Affibody.
Imaging agents
Affibody® Research Reagent | Catalog number | Size | Price |
---|---|---|---|
Anti-EGFR imaging agent |
10.2023.01.0005 |
500 µg |
€ 715 |
Anti-EGFR imaging agent |
10.2023.01.0001 |
100 µg |
€ 170 |
Anti-HER2, imaging agent |
10.1861.01.0001 |
100 µg |
€ 315 |
Anti-HER2, imaging agent |
10.1861.01.0005 |
500 µg |
€ 1 455 |
Imaging agent negative control |
10.2046.01.0005 |
500 µg |
€ 465 |
EGFR
Affibody® Research Reagent | Catalog number | Size | Price |
---|---|---|---|
Anti-EGFR unconjugated |
10.1886.01.0001 |
100 µg |
€ 170 |
Anti-EGFR unconjugated |
10.1886.01.0005 |
500 µg |
€ 465 |
Anti-EGFR, fluorescein conjugated |
10.1886.03.0001 |
100 µg |
€ 465 |
Anti-EGFR, agarose immobilized |
10.1246.04.0002 |
200 µl |
€ 550 |
Anti-EGFR, IP kit |
10.1246.04.9002 |
200 µl |
€ 615 |
HER2
Affibody® Research Reagent | Catalog number | Size | Price |
---|---|---|---|
Anti-HER2, unconjugated |
10.0817.01.0001 |
100 µg |
€ 170 |
Anti-HER2, unconjugated |
10.0817.01.0005 |
500 µg |
€ 465 |
Anti-HER2, biotin conjugated |
10.0817.02.0001 |
100 µg |
€ 465 |
Anti-HER2, fluorescein conjugated |
10.0817.03.0001 |
100 µg |
€ 465 |
Anti-HER2, agarose immobilized |
10.0817.04.0002 |
200 µl |
€ 550 |
Anti-HER2, IP kit |
10.0817.04.9002 |
200 µl |
€ 615 |
Anti-HER2, HRP conjugated |
10.0817.05.0002 |
200 µl |
€ 465 |
HSA
Affibody® Research Reagent | Catalog number | Size | Price |
---|---|---|---|
Anti-HSA, unconjugated |
10.0644.01.0010 |
1 mg |
€ 715 |
Anti-HSA, unconjugated |
10.0644.01.0050 |
5 mg |
€ 2 495 |
Anti-HSA, biotin conjugated |
10.0644.02.0005 |
500 µg |
€ 715 |
IgA
Affibody® Research Reagent | Catalog number | Size | Price |
---|---|---|---|
Anti-IgA, unconjugated |
10.1150.01.0005 |
500 µg |
€ 395 |
Anti-IgA, unconjugated |
10.1150.01.0050 |
5 mg |
€ 2 495 |
IgE
Affibody® Research Reagent | Catalog number | Size | Price |
---|---|---|---|
Anti-IgE, unconjugated |
10.0816.01.0010 |
1 mg |
€ 715 |
IgG
Affibody® Research Reagent | Catalog number | Size | Price |
---|---|---|---|
Anti-IgG, unconjugated |
10.0623.01.0010 |
1 mg |
€ 715 |
Anti-IgG, unconjugated |
10.0623.01.0050 |
5 mg |
€ 2 495 |
Anti-IgG, biotin conjugated |
10.0623.02.0005 |
500 µg |
€ 715 |
IgM
Affibody® Research Reagent | Catalog number | Size | Price |
---|---|---|---|
Anti-IgM, unconjugated |
10.1329.01.0005 |
500 µg |
€ 465 |
Anti-IgM, unconjugated |
10.1329.01.0050 |
5 mg |
€ 2 495 |
Insulin
Affibody® Research Reagent | Catalog number | Size | Price |
---|---|---|---|
Anti-Insulin, unconjugated |
10.0814.01.0010 |
1 mg |
€ 715 |
Anti-Insulin, unconjugated |
10.0814.01.0050 |
5 mg |
€ 2 495 |
TNF-α
Affibody® Research Reagent | Catalog number | Size | Price |
---|---|---|---|
Anti-TNF-α, unconjugated |
10.0841.01.0010 |
1 mg |
€ 715 |
Anti-TNF-α, unconjugated |
10.0841.01.0050 |
5 mg |
€ 2 495 |
Anti-TNF-α, agarose immobilized |
10.0841.04.0002 |
200 µl |
€ 465 |
Anti-TNF-α, IP kit |
10.0841.04.9002 |
200 µl |
€ 595 |
Transferrin
Affibody® Research Reagent | Catalog number | Size | Price |
---|---|---|---|
Anti-Transferrin, unconjugated |
10.1105.01.0005 |
500 µg |
€ 465 |
Anti-Transferrin, unconjugated |
10.1105.01.0050 |
5 mg |
€ 2 495 |
Fibrinogen
Affibody® Research Reagent | Catalog number | Size | Price |
---|---|---|---|
Anti-Fibrinogen, unconjugated |
10.1278.01.0005 |
500 µg |
€ 465 |
Anti-Fibrinogen, unconjugated |
10.1278.01.0050 |
5 mg |
€ 2 495 |
Affibody
Affibody® Research Reagent | Catalog number | Size | Price |
---|---|---|---|
Goat Anti-Affibody® IgG |
20.1000.01.0005 |
500 µl |
€ 395 |
Affibodys latest Press releases
2021-03-09
Affibody in short
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
Upcoming reports Financial calendar
- Interim Report January to March 2020 (May 15, 2020)
- Interim Report January to June 2020 (August 21, 2020)
- Interim Report January to September 2020 (November 13, 2020)
- Year End Report 2020 (February 2021)